Minu Samanta
Children's Hospital of Philadelphia · 50 works · 3,468 citations · h-index 17
Top works
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- Human cytomegalovirus infection and expression in human malignant glioma.
- Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer
- High Prevalence of Human Cytomegalovirus in Prostatic Intraepithelial Neoplasia and Prostatic Carcinoma
- Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells.
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
- Evidence for Peroxynitrite-Mediated Modifications to p53 in Human Gliomas: Possible Functional Consequences
- CharacterizationCSMD1in a large set of primary lung, head and neck, breast and skin cancer tissues
- Antigenic and Mutational Analyses of Herpes Simplex Virus Glycoprotein B Reveal Four Functional Regions
- PARP-1–Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma
- Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF V600E Conformation
- PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma
- BARD1germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma
- Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
- Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
- Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma
- Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma
- Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells
- The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity
- PARP-1 Targeted Alpha-emitting Radiotherapeutics: An Examination of Potential Toxicity